本土益生菌对高胆固醇饮食诱导的高胆固醇贫血大鼠的有益作用
Narathip Puttarat1,2, Anongnard Kasorn3, Porntipha Vitheejongjaroen1,2
1Center of Excellence in Probiotics, Srinakharinwirot University, Bangkok 10110, Thailand.
Nutrients
|June 28, 2023
概括
益生菌可以降低胆固醇水平,改善肠道健康. 特定的菌株,单独或一起使用时,为管理高胆固醇和相关疾病提供协同效应.
科学领域:
- 微生物学 微生物学
- 营养科学 营养科学
- 胃肠病学 胃肠病学
背景情况:
- 高胆固醇血症是心血管疾病和代谢障碍的主要危险因素.
- 益生菌,有益的肠道微生物群,具有降胆固醇的特性.
- 益生菌干预提供了一种潜在的策略,可以在没有不良影响的情况下管理胆固醇代谢.
研究的目的:
- 为了研究单个和组合益生菌菌株的低胆固醇效应.
- 为了评估Limosilactobacillus reuteri TF-7,Enterococcus faecium TF-18和Bifidobacterium animalis TA-1的影响.
- 在高胆固醇饮食引起的高胆固醇血症的小鼠模型中评估益生菌的疗效.
主要方法:
- 在使用高胆固醇饮食 (HCD) 的老鼠中诱导高胆固醇血症.
- 单个和混合益生菌菌株 (L. reuteri TF-7,E. faecium TF-18,B. animalis TA-1) 的使用.
- 评估体重增加,内脏器官指数,脂质概况,肝肥胖症和肠道微生物群组成.
主要成果:
- 单次服用益生菌可以减少体重增加,内脏器官指数,高脂血症和肝硬化.
- 益生菌治疗改善了整体的胃肠道微生物群.
- 三种益生菌菌株的同时使用显示出协同作用的低胆固醇效应.
结论:
- 研究的益生菌菌株表现出显著的低胆固醇效应.
- 一种L. reuteri TF-7,E. faecium TF-18和B. animalis TA-1的组合显示出协同效益.
- 这些益生菌是减轻胆固醇相关疾病风险的补充剂的有希望的候选者.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
706
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
706
01:29Cholesterol: Significance and Regulation
605
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
605
01:26Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15